Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPARgamma1 but not that for the adipocyte-specific gamma2 isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL). Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPARgamma mRNA level in HSC from BDL. Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-1 binding were increased. Treatment of cultured-activated HSC with ligands for PPARgamma (10 microm 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)); 0.1 approximately 10 microm BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2) was abrogated 70% by the concomitant treatment with a PPARgamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPARalpha and gamma (>100 microm) but not at those that only activate PPARalpha (<10 microm) or by a synthetic PPARalpha-selective agonist (GW9578). 15dPGJ(2) reduced alpha1(I) procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36. 15dPGJ(2) and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor alpha (10 ng/ml) reduced PPARgamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2). These results demonstrate that HSC activation is associated with the reductions in PPARgamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPARgamma ligands in vitro. These findings implicate diminished PPARgamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPARgamma ligands for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIG. 4 A , PPAR g (15dPGJ2, BRL49653) ligands inhibit HSC DNA and collagen synthesis. The 3-4-day primary cultures of HSC were exposed to 15dPGJ2 (1 and 10 m M), BRL49653 (1 and 10 m M), or WY14643 (10 ; 250 m M) for 18 h, and [ 3 H]thymidine incorporation into DNA was assessed. Note a significant, ; 40%, inhibition in HSC DNA synthesis by 15dPGJ2 and BRL49653 at 10 m M and WY14643 at 100 and 250 m M. *, p , 0.05; **, p , 0.01 compared with the respective control. DMSO , Me2SO. B , collagen production by cultured HSC, as determined by incorporation of [ 3 H]proline into collagenase-sensitive peptides was significantly inhibited by 18 h of treatment with 15dPGJ 2 (10 m M), BRL49653 (0.1 ; 10 m M), and WY14643 (100 m M). *, p , 0.05; **,](https://figures.cochat.ai/paper-figures/a66e36c4743842c5bde9349747bed49a/peroxisome-proliferator-activated-receptors-and-hepatic-stellate-cell-activation-figure-4.png)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist with anticholestatic, 14 anti-inflammatory, 15 and antifibrotic 16 properties”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationThomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 9
- Friedman, S. L., Wei, S., and Blaner, W. S. (1993) Am. J. Physiol. 264, G947-G952
- Tsukamoto, H., Cheng, S., and Blaner, W. S. (1996) Am. J. Physiol. 270, G581-G586
- Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
- Okuno, M., Moriwaki, H., Imai, S., Muto, Y., Kawada, N., Suzuki, Y., and Kojima, S. (1997) Hepatology 26, 913-921
- Potter, J. J., Womack, L., Mezey, E., and Anania, F. A. (1998) Biochem. Cell Biol.244, 178 -182
- Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., and Tsukamoto, H. (1997) Am. J. Physiol. 272, G1355-G1364
- Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251
- Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B. M., and Moller, D. E. (1996) Mol. Endocrinol. 10, 1457-1466
- Tsukamoto, H. (1999) Alcohol Clin. Exp. Res. 23, 911-916 · doi:10.1111/j.1530-0277.1999.tb04202.x · Paper page
Cited by
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
“Third, stellate cell activation is associated with downregulation of PPARg signaling, and ligands of PPARg but not PPARa downregulate stellate cell activation[57,58].”
BackgroundLiver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“Other molecular mechanisms involved in fibrosis include PPAR isoforms; experimental work concluded that suppression of PPARγ is required for HSC activation (206), with ligands for PPARγ reverting the activated phenotype of HSCs in vitro and abrogating fibrosis in vivo (207).”
BackgroundPeroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Self-citationPPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
“Compared with hepatocytes and Kupffer cells, PPARγ2 is highly expressed in quiescent HSC, and PPARγ is down-regulated during HSC activation [87].”
BackgroundHemmann, S., Graf, J., Roderfeld, M., & Roeb, E. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.003 · Cited by 509
Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications
Friedman, S. L. (2004) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0055 · Cited by 498
“A growing number of transcription factors could regulate stellate cell behavior, including peroxisomal proliferator activated receptors (PPARs) α, β and γ”
BackgroundEnhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin
Kamada, Y., Tamura, S., Kiso, S., Matsumoto, H., Saji, Y., Yoshida, Y., Fukui, K., Maeda, N., Nishizawa, H., Nagaretani, H., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.029 · Cited by 479
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
MeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and Fibrosis
Mann, J., Chu, D. C. K., Maxwell, A., Oakley, F., Zhu, N., Tsukamoto, H., & Mann, D. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.002 · Cited by 397
Self-citationFu, Y., Zheng, S., Lin, J., Ryerse, J., & Chen, A. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.039818 · Cited by 394
“In addition, HSC activation coincides with a dramatic reduction in the abundance of PPAR (Marra et al., 2000; Miyahara et al., 2000), which might play an important role in hepatic fibrogenesis.”
BackgroundIp, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
“A decrease in PPAR-γ expression in target tissues accompanies progression of fibrosis in experimental models of lung, liver and kidney fibrosis, and in normal aging”
Hepatic stellate cells in physiology and pathology
Kamm, D. R., & McCommis, K. S. (2022) · The Journal of Physiology · doi:10.1113/jp281061 · Cited by 325
“Enhancement of PPAR γ and SREBP-1c expression or activity prevents or reverses HSC activation, suggesting that maintenance of the adipogenic phenotype maintains quiescence (Miyahara et al., 2000; She et al., 2005; Tsukamoto, 2005).”
InfluentialTsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Self-citationLiver fibrosis: from the bench to clinical targets
Pinzani, M., & Rombouts, K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.003 · Cited by 336
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Self-citationAdipogenic Transcriptional Regulation of Hepatic Stellate Cells
She, H., Xiong, S., Hazra, S., & Tsukamoto, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410078200 · Cited by 299
Self-citationRoles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Multigenerational epigenetic adaptation of the hepatic wound-healing response
Zeybel, M., Hardy, T., Wong, Y. K., Mathers, J. C., Fox, C. R., Gackowska, A., Oakley, F., Burt, A. D., Wilson, C. L., Anstee, Q. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2893 · Cited by 279
“This differential expression of PPAR-γ is relevant since ectopic re-expression in myofibroblasts can reverse their phenotype into a more quiescent state 21, 23 .”
Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., & Szabo, G. (2009) · Hepatology · doi:10.1002/hep.22711 · Cited by 263
Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat
Iimuro, Y., Nishio, T., Morimoto, T., Nitta, T., Stefanovic, B., Choi, S. K., Brenner, D. A., & Yamaoka, Y. (2003) · Gastroenterology · doi:10.1053/gast.2003.50063 · Cited by 263
Fibrosis in chronic liver diseases: diagnosis and management
Pinzani, M., Rombouts, K., & Colagrande, S. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.008 · Cited by 267
“Modulation of pro-fibrogenic and proinflammatory actions in HSC [107,108]”
BackgroundWnt antagonism inhibits hepatic stellate cell activation and liver fibrosis
Cheng, J. H., She, H., Han, Y.-P., Wang, J., Xiong, S., Asahina, K., & Tsukamoto, H. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00263.2007 · Cited by 258
“Our previous studies demonstrate that the expression of adipogenic transcription factors is essential for the maintenance of HSC quiescence in vitro (7, 18, 28).”
BackgroundSelf-citationRegulation of Bile Acid and Cholesterol Metabolism by PPARs
Li, T., & Chiang, J. Y. L. (2009) · PPAR Research · doi:10.1155/2009/501739 · Cited by 241
“The use of PPAR agonists for treating steatohepatitis has also been considered due to their known effects in fatty acid metabolism, inflammation, and hepatic fibrosis [141–145].”
Frungieri, M. B., Weidinger, S., Meineke, V., Köhn, F. M., & Mayerhofer, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232422999 · Cited by 252
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
“PPARc ligands can inhibit stellate cell activation, including suppressing expression of collagen and smooth muscle actin, and these effects appear to require PPARc as they do not occur in the presence of a PPARc antagonist (Miyahara et al., 2000).”
BackgroundInfluentialInvolvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 239
de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Povero, D., Panera, N., Eguchi, A., Johnson, C. D., Papouchado, B. G., de Araujo Horcel, L., Pinatel, E. M., Alisi, A., Nobili, V., & Feldstein, A. E. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.07.007 · Cited by 221
“Notably, it has been shown that PPAR-g progressively decreases during HSC activation and that it is completely depleted in fully activated HSCs.(25,27) The findings that the internalization of EVs into HSCs resulted in the transfer of their RNA content into the HSCs, including various miRNAs that are specific modulato…”
BackgroundOró, D., Yudina, T., Fernández-Varo, G., Casals, E., Reichenbach, V., Casals, G., González de la Presa, B., Sandalinas, S., Carvajal, S., Puntes, V., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.020 · Cited by 215
“Abbreviations: a-SMA, a-smooth muscle actin; HSCs, hepatic stellate cells; NASH, non-alcoholic steatohepatitis; iNOS, inducible nitric oxide synthase; ROS, reactive oxygen species; NF-jb, nuclear factor j-b; TNF-a, tumor necrosis factor a; TMAOH, tetramethylammonium hydroxide; TEM, transmission electron microscopy; MR…”
BackgroundInfluentialXu, J., Fu, Y., & Chen, A. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00474.2002 · Cited by 221
“PPAR- ligands inhibit HSC proliferation and collagen- 1(I) expression in vitro (36).”
BackgroundInfluentialTargeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
“PPARγ, predominantly PPARγ2, is highly expressed in quiescent HSC compared as hepatocytes and Kupffer cells, and PPARγ is down-regulated during HSC activation (Miyahara et al., 2000).”
BackgroundHardy, T., Zeybel, M., Day, C. P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311526 · Cited by 216
“29 30 We have previously shown that the methyl-CpG binding protein MeCP2 brings about this repression of PPAR γ transcription at least in part by associating with methylated regions of the upstream promoter where it recruits chromatin remodelling factors.”
BackgroundMilam, J. E., Keshamouni, V. G., Phan, S. H., Hu, B., Gangireddy, S. R., Hogaboam, C. M., Standiford, T. J., Thannickal, V. J., & Reddy, R. C. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00333.2007 · Cited by 211
“Ligands of PPAR- inhibit activation of a variety of mesenchymal and fibroblast cell types (15, 18, 33, 39, 42, 55, 73).”
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Oncotarget · doi:10.18632/oncotarget.21234 · Cited by 204
“PPAR γ natural and synthetic ligands, such as 15d-PGJ2 and rosiglitazone, can decrease the fibroblast-myofibroblast differentiation, synthesis of collagen and firbonectin and decrease the expression of TGF-β1 [247, 248, 253, 258, 259].”
BackgroundExposure to fine airborne particulate matters induces hepatic fibrosis in murine models
Zheng, Z., Zhang, X., Wang, J., Dandekar, A., Kim, H., Qiu, Y., Xu, X., Cui, Y., Wang, A., Chen, L. C., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.020 · Cited by 200
Fate-Mapping Evidence That Hepatic Stellate Cells Are Epithelial Progenitors in Adult Mouse Livers
Yang, L., Jung, Y., Omenetti, A., Witek, R. P., Choi, S., Vandongen, H. M., Huang, J., Alpini, G. D., & Diehl, A. M. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0115 · Cited by 203
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
Hyogo, H., Tazuma, S., Arihiro, K., Iwamoto, K., Nabeshima, Y., Inoue, M., Ishitobi, T., Nonaka, M., & Chayama, K. (2008) · Metabolism · doi:10.1016/j.metabol.2008.07.030 · Cited by 206
“The PPARγ has been demonstrated to attenuate the inflammatory response by inhibiting the production of TNF-α in monocytes [47]; to reduce interleukin-6 [46], a powerful inducer of CRP; and to reduce profibrogenic and proinflammatory actions in hepatic stellate cells [48,49].”
BackgroundTGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts
Vallée, A., & Lecarpentier, Y. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0362-3 · Cited by 194
Ghosh, A. K., Bhattacharyya, S., Lakos, G., Chen, S., Mori, Y., & Varga, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20104 · Cited by 201
Wei, J., Ghosh, A. K., Sargent, J. L., Komura, K., Wu, M., Huang, Q.-Q., Jain, M., Whitfield, M. L., Feghali-Bostwick, C., & Varga, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013778 · Cited by 193
“Additionally, the expression of PPAR-c is markedly diminished in lesional tissues in rodent models of fibrosis and scleroderma [21,22,23], as well as in lesional skin from patients with cicatrical (scarring) alopecia [24].”
BackgroundA role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
Skat‐Rørdam, J., Højland Ipsen, D., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13190 · Cited by 192
“This could be explained by a decrease in PPARγ expression concomitant with HSC activation, reducing TZD effects by diminishing target availability.(57,59) While clinical trials have suggested anti‐ steatogenic and anti‐inflammatory actions of pioglitazone, and to a lesser degree rosiglitazone, the effects on fibrosis…”
BackgroundZhou, X., Zang, X., Ponnusamy, M., Masucci, M. V., Tolbert, E., Gong, R., Zhao, T. C., Liu, N., Bayliss, G., Dworkin, L. D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040457 · Cited by 186
Transcriptional regulation of hepatic stellate cell activation: Figure 1
Mann, D. A., & Smart, D. E. (2002) · Gut · doi:10.1136/gut.50.6.891 · Cited by 190
Adachi, M., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.21991 · Cited by 181
Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2
Lee, Y. K., Park, J. E., Lee, M., & Hardwick, J. P. (2018) · Liver Research · doi:10.1016/j.livres.2018.12.001 · Cited by 173
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Souza-Mello, V. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1012 · Cited by 182
Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy
Wei, J., Bhattacharyya, S., Tourtellotte, W. G., & Varga, J. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.09.015 · Cited by 173
Fiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Morelli, A., Pruzanski, M., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085597 · Cited by 177
“PPARβ and -γ have been found in rat and human HSCs (Galli et al., 2000; Hellemans et al., 2003; Marra et al., 2000; Miyahara et al., 2000).”
BackgroundZhang, A.-S., Xiong, S., Tsukamoto, H., & Enns, C. A. (2004) · Blood · doi:10.1182/blood-2003-07-2378 · Cited by 174
Self-citationFibrotic disorders in the eye: Targets of gene therapy
Saika, S., Yamanaka, O., Sumioka, T., Miyamoto, T., Miyazaki, K.-I., Okada, Y., Kitano, A., Shirai, K., Tanaka, S.-I., & Ikeda, K. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.002 · Cited by 173
Biliary Complications and Outcomes of Liver Transplantation from Donors after Cardiac Death
Maheshwari, A., Maley, W., Li, Z., & Thuluvath, P. J. (2007) · Liver Transplantation · doi:10.1002/lt.21212 · Cited by 171
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies
Li, J.-T., Liao, Z.-X., Ping, J., Xu, D., & Wang, H. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2180-y · Cited by 167
“Expression of PPARγ protein is dramatically reduced in activated HSCs both in vitro (human and rat cells) and in vivo.(59) Culture-activated HSCs can be phenotypically and functionally reversed to cells with the quiescent phenotype by forced expression of PPARγ.”
BackgroundInfluentialLiu, Y., Wang, Z., Kwong, S. Q., Lui, E. L. H., Friedman, S. L., Li, F. R., Lam, R. W. C., Zhang, G. C., Zhang, H., & Ye, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.035 · Cited by 168
“To further define the mechanisms of Nilotinib on activated HSCs, we evaluated whether Nilotinib affects PPARc, which is dramatically reduced during HSC activation [21].”
BackgroundCurrent and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Rockey, D. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.011 · Cited by 163
Bendixen, A. C., Shevde, N. K., Dienger, K. M., Willson, T. M., Funk, C. D., & Pike, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041493198 · Cited by 161
Self-citationMechanisms of alcohol‐induced hepatic fibrosis: A summary of the Ron Thurman Symposium†
Purohit, V., & Brenner, D. A. (2006) · Hepatology · doi:10.1002/hep.21107 · Cited by 161
Alcohol induced hepatic fibrosis: Role of acetaldehyde
Mello, T., Ceni, E., Surrenti, C., & Galli, A. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.10.001 · Cited by 160
Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D., & Brenner, D. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.033 · Cited by 165
Jiménez-Flores, L. M., López-Briones, S., Macías-Cervantes, M. H., Ramírez-Emiliano, J., & Pérez‐Vázquez, V. (2014) · Molecules · doi:10.3390/molecules19068289 · Cited by 165
“increased [45–47].”
Fatty Liver Disease: NASH and Related Disorders
(2004) · Wiley eBooks · doi:10.1002/9780470987438 · Cited by 154
Molecular regulation of pancreatic stellate cell function.
Jaster, R. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-26 · Cited by 173
“Recent studies have implicated the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) in the inhibition of stellate cell activation in liver [67-69] and pancreas [69]: The PPARγ ligands 15-deoxy∆12,14-prostaglandin J2 and troglitazone (an antidiabetic drug of the thiazolidinedione group) act…”
BackgroundLiver Fibrogenesis: A New Role for the Renin–Angiotensin System
Bataller, R., Sancho-Bru, P., Ginês, P., & Brenner, D. A. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1346 · Cited by 154
Son, G., Hines, I. N., Lindquist, J., Schrum, L. W., & Rippe, R. A. (2009) · Hepatology · doi:10.1002/hep.23186 · Cited by 162
Self-citation15-Deoxy-Δ12,14-prostaglandin J2 Induces Apoptosis of Human Hepatic Myofibroblasts
Li, L., Tao, J., Davaille, J., Féral, C., Mallat, A., Lotersztajn, S., Rieusset, J., & Vidal, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101980200 · Cited by 156
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 157
Nati, M., Haddad, D., Birkenfeld, A. L., Koch, C. A., Chavakis, T., & Chatzigeorgiou, A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9339-2 · Cited by 144
Hellemans, K., Michalik, L., Dittie, A., Knorr, A., Rombouts, K., de Jong, J., Heirman, C., Quartier, E., Schuit, F., Wahli, W., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50015 · Cited by 137
Sertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809010-00002 · Cited by 151
Friedman, S. L., Maher, J. J., & Bissell, M. D. (2000) · Hepatology · doi:10.1053/jhep.2000.20243 · Cited by 141
The Role of PPARs in Lung Fibrosis
Lakatos, H. F., Thatcher, T. H., Kottmann, R. M., Garcia, T. M., Phipps, R. P., & Sime, P. J. (2007) · PPAR Research · doi:10.1155/2007/71323 · Cited by 139
“Differentiation of hepatic stellate cells to a myofibroblast phenotype is a key step in liver fibrosis [80–82].”
BackgroundPlanagumà, A., Clària, J., Miquel, R., López‐Parra, M., Titos, E., Masferrer, J. L., Arroyo, V., & Rodé, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2753fje · Cited by 133
“PPARγ plays a pivotal role in the progression of liver fibrosis since HSC activation is associated with a reduction in both expression and transcriptional activity of this nuclear receptor (26, 27).”
BackgroundBeaven, S. W., Wroblewski, K., Wang, J., Hong, C., Bensinger, S., Tsukamoto, H., & Tontonoz, P. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.053 · Cited by 131
Self-citationYang, M. D., Chiang, Y., Higashiyama, R., Asahina, K., Mann, D. A., Mann, J., Wang, C. C. C., & Tsukamoto, H. (2011) · Hepatology · doi:10.1002/hep.24792 · Cited by 144
“A fat-storing phenotype is a unique and distinct feature of quiescent HSCs, and a decade ago our laboratory proposed that there is a regulatory commonality between adipocytes and quiescent HSCs.(6) Germane to this proposal is the expression and regulation by the master adipogenic transcription factor peroxisomal proli…”
BackgroundInfluentialSelf-citationTroglitazone and liver injury: In search of answers†
Chojkier, M. (2005) · Hepatology · doi:10.1002/hep.20567 · Cited by 125
Farnesoid X Receptor: From Structure to Potential Clinical Applications
Pellicciari, R., Costantino, G., & Fiorucci, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0582221 · Cited by 130
Paik, Y.-H., Kim, J. K., Lee, J. I., Kang, S. H., Kim, D. Y., An, S. H., Lee, S. J., Lee, D. K., Han, K.-H., Chon, C. Y., et al. (2009) · Gut · doi:10.1136/gut.2008.157420 · Cited by 127
“PPARγ ligands inhibit cell proliferation and collagen α1(I) expression in HSCs.”
BackgroundUpregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation
Zheng, F., Fornoni, A., Elliot, S. J., Guan, Y., Breyer, M. D., Striker, L. J., & Striker, G. E. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00189.2001 · Cited by 125
“Second, ligand-induced activation of PPAR inhibited type I collagen promoter activity and decreased 1 type I collagen mRNA levels in hepatic stellate cells (26).”
BackgroundBerthier, A., Johanns, M., Zummo, F. P., Lefebvre, P., & Staels, B. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166097 · Cited by 125
“In HSCs, selective agonism of the major isotype PPARγ (mostly PPARγ1, [59]) with thiazolidinediones (TZDs) decreased cell activation, collagen(I) production, and reduced proliferation and inflammatory chemotaxis as encountered in NAFLD [60,61].”
BackgroundSamuhasaneeto, S., Thong‐Ngam, D., Kulaputana, O., Suyasunanont, D., & Klaikeaw, N. (2009) · BioMed Research International · doi:10.1155/2009/981963 · Cited by 141
DE GOTTARDI, A., PAZIENZA, V., PUGNALE, P., BRUTTIN, F., RUBBIA‐BRANDT, L., JUGE‐AUBRY, C. E., MEIER, C. A., HADENGUE, A., & NEGRO, F. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02729.x · Cited by 119
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Zhao, X., Gonzales, N., & Aronowski, J. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12350 · Cited by 120
Nosjean, O., & Boutin, J. A. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00281-9 · Cited by 132
Transcriptional regulation of hepatic stellate cells
Mann, J., & Mann, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.011 · Cited by 119
“PPARγ is mainly expressed in adipose tissue where it regulates lipid metabolism and adipocyte differentiation [116–118].”
BackgroundPPARs Mediate Lipid Signaling in Inflammation and Cancer
Michalik, L., & Wahli, W. (2008) · PPAR Research · doi:10.1155/2008/134059 · Cited by 117
“Several PPARγ agonists inhibit the proliferation of human malignant melanomas [79], and the PPARα agonist fenofibrate has antimetastatic effects on melanoma tumors in vivo in a hamster model [80].”
BackgroundSertznig, P., Seifert, M., Tilgen, W., & Reichrath, J. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20998 · Cited by 121
Mahmoud, A. M. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0204 · Cited by 137
“In addition, several studies indicated that PPARγ deficiency in hepatic stellate cells is associated with a transdifferentiation and activation of these cells leading to excessive formation of fibrotic tissue in the liver (Miyahara et al. 2000; Zhang et al. 2012).”
BackgroundBisht, S., Khan, M. A., Bekhit, M., Bai, H., Cornish, T. C., Mizuma, M., Rudek, M. A., Zhao, M., Maitra, A., Ray, B., et al. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.86 · Cited by 125
Molecular basis of hepatic fibrosis
Hui, A. Y., & Friedman, S. L. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403005684 · Cited by 118
Antifibrotic therapy in chronic liver disease
Rockey, D. C. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00445-8 · Cited by 120
Zheng, S., & Chen, A. (2004) · Biochemical Journal · doi:10.1042/bj20040928 · Cited by 123
Morán‐Salvador, E., Titos, E., Rius, B., González‐Périz, A., García‐Alonso, V., López‐Vicario, C., Miquel, R., Barak, Y., Arroyo, V., & Clària, J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.023 · Cited by 121
“Consistent with previous studies [3,4], PPARc protein was significantly depleted in activated HSCs (Fig.”
The stellate cell system (vitamin A-storing cell system)
Senoo, H., Mezaki, Y., & Fujiwara, M. (2017) · Anatomical Science International · doi:10.1007/s12565-017-0395-9 · Cited by 123
“Three groups reported independently almost at the same time that PPARc ligands could inhibit HSC activation (Galli et al. 2000; Marra et al. 2000; Miyahara et al. 2000).”
BackgroundInfluential
Metadata
- Authors
- Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Maryland, College Park (US)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 46
- Pages
- 35715-35722
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2025657436
- Cited by
- 473
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 17 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7274 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs
- University of Southern California (DK48522)
- National Institutes of Health (5k08dk002450-05, AA10459)
- National Institute on Alcohol Abuse and Alcoholism (AA10459, R37AA006603, R37-AA-06603, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-02450)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- peroxisome proliferator-activated receptors, PPARγ, hepatic stellate cell activation, liver fibrosis, cholestatic liver fibrosis, bile duct ligation, PPAR ligands, collagen synthesis, PPAR-responsive element, TNF-α, matrix metalloproteinase-3
- MeSH terms
- Rosiglitazone, Animals, Cell Survival, Cells, Cultured, Collagen, DNA, Gene Expression Regulation, Liver, Liver Cirrhosis, Biliary, Liver Cirrhosis, Experimental, Male, Promoter Regions, Genetic, Protein Binding, Pyrimidines, RNA, Messenger, Thiazoles, Transcription Factors, Tumor Necrosis Factor-alpha, Prostaglandin D2, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Protein Isoforms, Thiazolidinediones, Cell Size, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.